AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01164813
Drug: Relafen
RxNorm normalized name: Relafen
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
Trial: NCT02576249
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4cc 0.5% ropivacaine
Trial: NCT02576249
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1cc 40mg methylprednisolone
Trial: NCT00389636
Drug: Regranex
RxNorm normalized name: Regranex
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regranex + TheraGauze
Trial: NCT02437136
Drug: entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An orally available histone deacetylases inhibitor (HDACs)
Trial: NCT02437136
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A selective humanized monoclonal antibody (mAb)
Trial: NCT00037596
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00037596
Drug: cytarabine.
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02509273
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02509273
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04212949
Drug: Transforaminal epidural steroid injection
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)
Trial: NCT00921336
Drug: KW-2450
RxNorm normalized name: KW-7158
DrugBank: KW-2450 free base (DB16637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation may proceed once \>= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
Trial: NCT04340505
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
Trial: NCT03671044
Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
Trial: NCT03671044
Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
Trial: NCT00760266
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
Trial: NCT00760266
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
Trial: NCT05488613
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
Trial: NCT00695409
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00695409
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00695409
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00695409
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04882618
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
Trial: NCT01934023
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Champix (Varenicline) is an approved smoking cessation medication
Trial: NCT02234466
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
Trial: NCT02234466
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
Trial: NCT04164355
Drug: Tadalafil 20 MG
RxNorm normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
Trial: NCT03928496
Drug: AbobotulinumtoxinA
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
Trial: NCT00261222
Drug: Amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00839891
Drug: VI-0521
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
Trial: NCT04366232
Drug: Anakinra alone (stages 2b/3)
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
Trial: NCT04366232
Drug: Anakinra and Ruxolitinib (overcome stage 3)
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
Trial: NCT03380962
Drug: Clazakizumab
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
Trial: NCT04117178
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjustment of treatment with donepezil according to serum level.
Trial: NCT04117178
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjustment of treatment with memantine according to serum level.
Trial: NCT03525873
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01216761
Drug: Iodine tincture
RxNorm normalized name: Iodine tincture
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
Trial: NCT03328026
Drug: Interferon Inoculation
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
Trial: NCT03328026
Drug: retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
Trial: NCT01783171
Drug: Akt Inhibitor MK2206
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01783171
Drug: Dinaciclib
RxNorm normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01309607
Drug: paclitaxel/carboplatin/lapatinib
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug doses for the neoadjuvant regimen:~* Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~* Lapatinib 750mg daily continuously
Trial: NCT01216761
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
Trial: NCT01216761
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
Trial: NCT03083171
Drug: Adrecizumab
RxNorm normalized name: Adrecizumab
DrugBank: Enibarcimab (DB16730)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
Trial: NCT03652077
Drug: INCAGN02390
RxNorm normalized name: INCAGN02390
DrugBank: Verzistobart (DB18895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
Trial: NCT01500577
Drug: nimesulide
RxNorm normalized name: nimesulide
DrugBank: Nimesulide (DB04743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
Trial: NCT01056770
Drug: smallpox vaccine CJ-50300
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
Trial: NCT00332163
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
Trial: NCT00002662
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002662
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00006264
Drug: ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006264
Drug: zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03657160
Drug: Vedolizumab Placebo
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab placebo-matching IV infusion.
Trial: NCT03657160
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV infusion.
Trial: NCT01345045
Drug: ABT-639
RxNorm normalized name: ABT-639
DrugBank: ABT-639 (DB15055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-639 Twice Daily for six weeks.
Trial: NCT01345045
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
Trial: NCT01457469
Drug: nicotine replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive nicotine replacement patches
Trial: NCT04201093
Drug: Tavapadon
RxNorm normalized name: Tavapadon
DrugBank: Tavapadon (DB14899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive tavapadon 5 mg QD or 15 mg QD tablet once daily orally for 27 weeks.
Trial: NCT02590003
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00113347
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
Trial: NCT00113347
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg/m\^2 or 20 mg/m\^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
Trial: NCT02590003
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03733470
Drug: Sildenafil study group
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of 20 mg Sildenafil will be given one hour before CT imaging.
Trial: NCT03787732
Drug: Fluid Bolus
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 milliliters of an intravenous crystalloid solution of the operator's choosing
Trial: NCT00544518
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
Trial: NCT00544518
Drug: benfluorex
RxNorm normalized name: benfluorex
DrugBank: Benfluorex (DB09022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
Trial: NCT00981357
Drug: PF-04457845
RxNorm normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04457845 4 mg tablet once daily / matched placebo
Trial: NCT01561274
Drug: 2 ml bupivacaine
RxNorm normalized name: 2 ML bupivacaine hydrochloride 7.5 MG/ML Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 ml bupivacaine
Trial: NCT02844803
Drug: Combination of Metformin + S. Baicalensis
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: the combination therapy for 8 weeks
Trial: NCT02844803
Drug: Combination of Metformin + Placebo
RxNorm normalized name: combinations of barbiturates
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: the metformin single therapy for 8 weeks
Trial: NCT02693210
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 1g infusions of rituximab on Days 1 and 15
Trial: NCT00559481
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03344965
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
Trial: NCT03018366
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
Trial: NCT00559481
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02519413
Drug: dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: delayed release capsules
Trial: NCT04296149
Drug: Y90-DOTA-Tyr3-Octreotide
RxNorm normalized name: Dota-nal3-octreotide Ga-68
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
Trial: NCT04157491
Drug: anlotinib and anti PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
Trial: NCT01825993
Drug: L-BUPIVACAINE ; MORPHINE
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01825993
Drug: MORPHINE
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00448578
Drug: Quetiapine Fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00448578
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01743157
Drug: Biochemo + bevacizumab then ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)
Trial: NCT01786668
Drug: Tofacitinib 2 mg
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
Trial: NCT01786668
Drug: Tofacitinib 5 mg
RxNorm normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
Trial: NCT01184196
Drug: Swab area with ChloraPrep
RxNorm normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
Trial: NCT01786668
Drug: Tofacitinib 10 mg
RxNorm normalized name: tofacitinib 10 MG
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
Trial: NCT01591759
Drug: Citicoline
RxNorm normalized name: Citicoline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
Trial: NCT00006734
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00006734
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00006734
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04516174
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of dexmedetomidine.
Trial: NCT02242292
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04516174
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of saline, dosage and infusion method of saline are consistent with dexmedetomidine.